drugset

Drugs / Olvi-Vec

Follow last change 24 days ago re-read 3 minutes ago

Olvi-Vec

Developed for: ovarian cancer · peritoneal carcinomatosis · small cell lung carcinoma
Investigated by: Genelux GmbH · Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

Trials 2

today NCT07136285 · Ph 1/2 NCT02759588 · Ph 1/2

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT07136285	Jul 2023 → Dec 2026 expected	small cell lung carcinoma	Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.	Recruiting	No outcome recorded
Phase 1/2	NCT02759588	May 2016 → Dec 2021	fallopian tube cancer, ovarian cancer, peritoneal carcinomatosis	Genelux GmbH	Completed	Met primary

Press releases naming this drug 10 releases

Date	Issuer	Release
2026-09-09	Genelux GmbH	Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy genelux.com ↗
2026-01-05	Genelux GmbH	Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials genelux.com ↗
2025-03-25	Genelux GmbH	Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease genelux.com ↗
2025-03-25	Genelux GmbH	Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer genelux.com ↗
2024-10-22	Genelux GmbH	Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer genelux.com ↗
2023-11-27	Genelux GmbH	Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer genelux.com ↗
2023-07-10	Genelux GmbH	Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology genelux.com ↗
2023-05-25	Genelux GmbH	Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology genelux.com ↗
2022-09-21	Genelux GmbH	Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer genelux.com ↗
2020-09-16	Genelux GmbH	Genelux to Present Data from Phase 2 Trial of Olvi-Vec in Heavily Pre-treated Platinum-Resistant/Refractory Ovarian Cancer at ESMO Virtual Congress 2020 genelux.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Olvi-Vec	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02759588 ↗ 1 NCT07136285 ↗
Route	Other	“administered via intraperitoneal infusion” NCT02759588 ↗